|
CHD7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.10862446895044E-15 |
| Normal-vs-Stage2 |
5.33020000359485E-08 |
| Normal-vs-Stage3 |
1.66489044772788E-12 |
| Normal-vs-Stage4 |
5.55111512312578E-16 |
| Stage1-vs-Stage2 |
4.912000E-01 |
| Stage1-vs-Stage3 |
2.486400E-02 |
| Stage1-vs-Stage4 |
2.615100E-04 |
| Stage2-vs-Stage3 |
2.551600E-02 |
| Stage2-vs-Stage4 |
1.456630E-03 |
| Stage3-vs-Stage4 |
1.484580E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.71350000433802E-08 |
| Normal-vs-Asian |
8.39550651221543E-13 |
| Caucasian-vs-AfricanAmerican |
7.395400E-01 |
| Caucasian-vs-Asian |
3.202200E-01 |
| AfricanAmerican-vs-Asian |
7.995000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.82631687550838E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.571600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(41-60Yrs) |
1.86850535044414E-13 |
| Normal-vs-Age(61-80Yrs) |
1.65434332899395E-12 |
| Normal-vs-Age(81-100Yrs) |
1.617850E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.134400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.211800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.940200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.120400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.104600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.548000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.74809999978309E-07 |
| Classical-VS-Follicular |
7.433600E-01 |
| Classical-VS-Other |
2.346800E-01 |
| Classical-VS-Normal |
3.25349747143377E-11 |
| Tall-VS-Follicular |
3.60900000000441E-05 |
| Tall-VS-Other |
3.654200E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
2.699200E-01 |
| Follicular-VS-Normal |
7.77589992395633E-10 |
| Other-VS-Normal |
1.442010E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.88737914186277E-15 |
| Normal-vs-N1 |
1.62680979798324E-12 |
| N0-vs-N1 |
1.742800E-03 |
|
|
